531 related articles for article (PubMed ID: 9819046)
1. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
Petrini P; Klementz G
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
[TBL] [Abstract][Full Text] [Related]
2. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
3. Home treatment with recombinant activated factor VII: results from one centre.
Ingerslev J; Thykjaer H; Kudsk Jensen O; Fredberg U
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S107-10. PubMed ID: 9819039
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Stewart AJ; Hanley JP; Ludlam CA
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
[TBL] [Abstract][Full Text] [Related]
5. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment.
Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S111-4. PubMed ID: 9819040
[TBL] [Abstract][Full Text] [Related]
6. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
7. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
[TBL] [Abstract][Full Text] [Related]
8. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
9. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.
Kavakli K; Makris M; Zulfikar B; Erhardtsen E; Abrams ZS; Kenet G;
Thromb Haemost; 2006 Apr; 95(4):600-5. PubMed ID: 16601828
[TBL] [Abstract][Full Text] [Related]
10. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
Nicolaisen EM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
[TBL] [Abstract][Full Text] [Related]
11. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
Meili EO; Dazzi H; von Felten A
Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
[TBL] [Abstract][Full Text] [Related]
12. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
Brackmann HH; Effenberger W; Hess L; Schwaab R; Oldenburg J
Eur J Haematol Suppl; 1998; 63():18-23. PubMed ID: 9882928
[TBL] [Abstract][Full Text] [Related]
13. Development of anaphylactic shock in haemophilia B patients with inhibitors.
Warrier I; Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S125-8. PubMed ID: 9819043
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
Treur MJ; McCracken F; Heeg B; Joshi AV; Botteman MF; De Charro F; Van Hout B
Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
[TBL] [Abstract][Full Text] [Related]
15. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with activated factor VII: focus on safety aspects.
Roberts HR
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
[TBL] [Abstract][Full Text] [Related]
17. Bleeding and surgery in children with Glanzmann thrombasthenia with and without the use of recombinant factor VII a.
Hennewig U; Laws HJ; Eisert S; Göbel U
Klin Padiatr; 2005; 217(6):365-70. PubMed ID: 16307424
[TBL] [Abstract][Full Text] [Related]
18. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
Young G; Cooper DL; Gut RZ;
Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
20. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Brady KM; Easley RB; Tobias JD
Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]